Table 1 Clinical and pathological information for patients with dMMR and matched patients with pMMR
Group | Stage I&II dMMR (n = 32) | Stage III&IV dMMR (n = 32) | P value (I&II vs. III&IV) | Stage I-IV pMMR (n = 64) | P value (dMMR vs. pMMR) |
|---|---|---|---|---|---|
Age(year) | 62.66 ± 13.85 | 62.59 ± 17.35 | 0.987 | 62.84 ± 12.34 | 0.592 |
Sex, n (%) | Â | Â | 0.614 | Â | 1.000 |
 Male | 17 (53.1%) | 19 (59.4%) |  | 36 (56.3%) |  |
 Female | 15 (46.9%) | 13 (40.6%) |  | 28 (43.8%) |  |
BMI (kg/m2) | 23.84 ± 3.92 | 22.87 ± 3.15 | 0.280 | 24.44 (21.78–25.68) | 0.475 |
Tumor location | Â | Â | 0.805 | Â | 1.000 |
 Right-sided | 19 (59.4%) | 21 (65.6%) |  | 40 (62.5%) |  |
 Left-sided | 6 (18.8%) | 6 (18.8%) |  | 12 (18.8%) |  |
 Rectum | 7 (21.9%) | 5 (15.6%) |  | 12 (18.8%) |  |
UICC-TNM stage | Â | Â | / | Â | 1.000 |
 I | 8 (25%) |  |  | 8 (12.5%) |  |
 II | 24 (75%) |  |  | 24 (37.5%) |  |
 III |  | 28 (87.5%) |  | 28 (43.8%) |  |
 IV |  | 4 (12.5%) |  | 4 (6.2%) |  |
Tumor deposit | Â | Â | 0.148 | Â | 0.826 |
 Negative | 30 (93.8%) | 25 (78.1%) |  | 54 (84.4%) |  |
 Positive | 2 (6.2%) | 7 (21.1%) |  | 10 (15.6% |  |
PNI | Â | Â | 0.277 | Â | 0.219 |
 Negative | 29 (90.6%) | 26 (81.3%) |  | 48 (75.0%) |  |
 Positive | 3 (9.4%) | 6 (18.8%) |  | 16 (25.0%) |  |
Follow-up time | 51.14 (28.80–79.43) | 41.03 (19.24–61.76) | 0.151 | 49.26 (28.73–69.20) | 0.343 |
Length of hospital stay | 18.38 (11.25–25.5) | 19.09 (13–25.5) | 0.770 | 16.22 (13–18) | 0.550 |
Differentiation | Â | Â | 0.486 | Â | 0.046 |
 High | 1 (3.1%) | 0 |  | 2 (3.1%) |  |
 Medium | 19 (59.4%) | 17 (53.1%) |  | 48 (75.0%) |  |
 Low | 12 (37.5%) | 15 (46.9%) |  | 14 (21.9%) |  |